Detection of Locked Nucleic Acid and 2'-O-Methoxyethyl Gapmers from Mouse Samples Using ELISA.

Kenji Rowel Q Lim, Quynh Nguyen, Toshifumi Yokota

Abstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kenji Rowel Q LimCenter for Cardiovascular Research, Division of Cardiology, Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.

Quynh NguyenDivision of Cardiac Surgery, Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.

Toshifumi YokotaDepartment of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. toshifumi.yokota@ualberta.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antisense oligonucleotide (ASO)-mediated therapy is promising for the treatment of a variety of genetic disorders, as primarily seen for Duchenne muscular dystrophy. As more ASOs advance in therapeutic development and enter clinical trials, it becomes necessary to have a means of quantifying their amounts in biological samples post-treatment. This information will be valuable for evaluating the safety and pharmacokinetic profiles of ASOs, and also in deciding how the efficacy of these drugs can be improved. Gapmers are a class of ASOs characterized by having a central DNA segment that is surrounded by chemically modified nucleotides on both ends. While methods to quantify other ASOs, such as phosphorodiamidate morpholino oligomers (PMOs), have been extensively used in in vivo studies, the quantification of gapmers has been more limited. Here, we describe a sensitive enzyme-linked immunosorbent assay (ELISA)-based protocol that can be used to quantify the levels of locked nucleic acid (LNA) and 2'-O-methoxyethyl (2'-MOE) gapmers in mouse muscle tissue.

Indexed as

OligonucleotidesOligonucleotides, AntisenseAnimalsEnzyme-Linked Immunosorbent AssayMiceMorpholinoslocked nucleic acidMorpholinosOligonucleotidesOligonucleotides, Antisense2′-MOEAntisense oligonucleotidesAntisense therapyELISAGapmer quantificationGapmer uptakeIn vivo evaluationLNAPharmacokineticsSafety

Identifiers

PMID42814312

DOI10.1007/978-1-0716-0771-8_17

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.